GlassScriptPhysician profile
Dipali A Desai
NPI 1851671945
$8,183.15
in general payments reported to CMS, 2019-2025
45 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $748 · 2021: $1,321 · 2022: $894 · 2023: $1,417 · 2024: $1,283 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,219.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,267.17 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Glaxosmithkline, LLC. | $865.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $690.44 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $571.19 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $517.97 | 2019-2025 | |
| Olympus America INC. | $420.44 | 2025 | Itind System |
| Lilly USA, LLC | $370.46 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $278.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $276.49 | 2019-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.57 | 2020-2025 | Jardiance, Ofev, Spiriva Respimat |
| Amarin Pharma, INC. | $255.13 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.53 | 2021-2025 | |
| Coloplast Corp | $172.64 | 2019-2023 | |
| Astellas Pharma US INC | $159.25 | 2019-2025 | Veozah |
| Abbott Laboratories | $155.41 | 2024-2025 | Freestyle Libre 2 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipali Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.